TY - JOUR
T1 - Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction
AU - Agarwal, Richa
AU - Shah, Sanjiv J.
AU - Foreman, Aimee J.
AU - Glassner, Cherylanne
AU - Bartolome, Sonja D.
AU - Safdar, Zeenat
AU - Coslet, Sandra L.
AU - Anderson, Allen S.
AU - Gomberg-Maitland, Mardi
N1 - Funding Information:
The authors thank those individuals who have seen patients at the PH center and those who helped with data entry, including Jill Russo, RN, APN, Thenappan Thenappan, MD, and Tobias Perrino. We also thank Dave P. Miller for his excellent guidance and statistical support. Sanjiv J. Shah reports receiving research grants from the American Heart Association , the National Institutes of Health, Gilead Sciences, Actelion Pharmaceuticals , the American Society of Echocardiography , the Heart Failure Society of America , and Northwestern Memorial Foundation . Aimee J. Foreman is employed by ICON Clinical Research, a Contract Research Organization. Sonja D. Bartolome reports receiving research support from Actelion, Gilead, Bayer, LungRx, and United Therapeutics and has served on the speaker's bureau for Actelion, Gilead, and United Therapeutics. Zeenat Safdar has served as a consultant and/or advisory board member for Gilead, Actelion, and United Therapeutics. Allen S. Anderson reports receiving research support from Johnson and Johnson and XDx. Actelion, Gilead, Lilly/Icos, Pfizer, Novartis, and United Therapeutics have provided funding to the University of Chicago to support Dr. Gomberg-Maitland's conduct of clinical trials. She has served as a consultant Actelion, Gilead, Medtronic, Pfizer, and United Therapeutics. None of the other authors have a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose.
PY - 2012/5
Y1 - 2012/5
N2 - Background: Pulmonary hypertension (PH) is common in patients with left heart failure (HF), especially those with HF and preserved ejection fraction (HFpEF). However, there is limited data on risk stratification in these patients. Methods: Baseline clinical and hemodynamic variables of 339 patients with World Health Organization (WHO) Group 2 PH, 90% of whom had HFpEF, were studied to derive a multivariate Cox proportional hazards model. A simplified prognostic risk score was created based on the outcome of all-cause mortality. Nine predictors, significant after stepwise multivariable regression (p < 0.05), were used to create the risk score. Components of the risk score were functional class, diastolic blood pressure, pulmonary artery saturation, interstitial lung disease, hypotension on initial presentation, right ventricular hypertrophy, diffusion capacity of the lung for carbon monoxide, and 2 serum creatinine variables (≤ 0.9 mg/dl and < 1.4 mg/dl). Results: Overall 2-year survival was 73.8% ± 2.4% in the derivation cohort, and 87.5% ± 2.3%, 66.4% ± 4.9%, and 24.4% ± 6.7% for risk scores of 0 to 2, 3 to 4, and 5+, respectively (p < 0.0001 for the trend), with a C-index of 0.76 (95% confidence interval [CI], 0.71-0.81). The risk score was validated in 2 independent PH-HFpEF cohorts: 179 patients with a C-index of 0.68 (95% CI, 0.55-0.80) and 117 patients with a C-index of 0.68 (95% CI, 0.53-0.83). For the 3 cohorts combined (N = 635), the overall C-index was 0.72 (95% CI 0.68-0.76). In all 3 cohorts individually and in the 3 cohorts combined, the risk score predicted death (hazard ratio, 1.4-1.6; p < 0.01). Conclusions: Several clinical factors independently predict death in PH-HFpEF confirmed by validation. A novel risk score composed of these factors can be used to determine prognosis and may be useful in making therapeutic decisions.
AB - Background: Pulmonary hypertension (PH) is common in patients with left heart failure (HF), especially those with HF and preserved ejection fraction (HFpEF). However, there is limited data on risk stratification in these patients. Methods: Baseline clinical and hemodynamic variables of 339 patients with World Health Organization (WHO) Group 2 PH, 90% of whom had HFpEF, were studied to derive a multivariate Cox proportional hazards model. A simplified prognostic risk score was created based on the outcome of all-cause mortality. Nine predictors, significant after stepwise multivariable regression (p < 0.05), were used to create the risk score. Components of the risk score were functional class, diastolic blood pressure, pulmonary artery saturation, interstitial lung disease, hypotension on initial presentation, right ventricular hypertrophy, diffusion capacity of the lung for carbon monoxide, and 2 serum creatinine variables (≤ 0.9 mg/dl and < 1.4 mg/dl). Results: Overall 2-year survival was 73.8% ± 2.4% in the derivation cohort, and 87.5% ± 2.3%, 66.4% ± 4.9%, and 24.4% ± 6.7% for risk scores of 0 to 2, 3 to 4, and 5+, respectively (p < 0.0001 for the trend), with a C-index of 0.76 (95% confidence interval [CI], 0.71-0.81). The risk score was validated in 2 independent PH-HFpEF cohorts: 179 patients with a C-index of 0.68 (95% CI, 0.55-0.80) and 117 patients with a C-index of 0.68 (95% CI, 0.53-0.83). For the 3 cohorts combined (N = 635), the overall C-index was 0.72 (95% CI 0.68-0.76). In all 3 cohorts individually and in the 3 cohorts combined, the risk score predicted death (hazard ratio, 1.4-1.6; p < 0.01). Conclusions: Several clinical factors independently predict death in PH-HFpEF confirmed by validation. A novel risk score composed of these factors can be used to determine prognosis and may be useful in making therapeutic decisions.
KW - epidemiology
KW - heart failure
KW - prognosis
KW - pulmonary hypertension
UR - http://www.scopus.com/inward/record.url?scp=84859506585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859506585&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2011.11.017
DO - 10.1016/j.healun.2011.11.017
M3 - Article
C2 - 22221678
AN - SCOPUS:84859506585
SN - 1053-2498
VL - 31
SP - 467
EP - 477
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 5
ER -